About PDC*line Pharma
Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of plasmacytoid dendritic cells (PDC*line). PDC*line is much more potent than conventional Dendritic Cell-based vaccines to prime and boost antitumor antigen-specific cytotoxic T-cells, including T cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung, a candidate for non-small-cell lung cancer (NSCLC) and neoantigens (PDC*Neo). A phase Ib/IIa trial, aimed at evaluating safety and activity with and without anti-PD1, is being initiated in 2019 with PDC*lung. The company has a staff of 20 people, with an experienced management team. The company has so far raised €17M ($19.3M) including €7.6M ($8.6M) in equity and loans from Belgian investors (MeusInvest, Innodem3, InvestSud and SFPI) and several business angels, and €9.3M ($10.5M) of non-dilutive money (including grants from the Walloon region, Belgium and French entities).
State of Ownership